GlassScriptPhysician profile
Michael Ashamalla
NPI 1427589423
$5,583.12
in general payments reported to CMS, 2019-2025
22 companies · $4,176 in 2025
The $4,176 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,407 · 2025: $4,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,583.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $1,073.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $972.11 | 2024-2025 | |
| Genzyme Corporation | $708.36 | 2024-2025 | |
| Intra-Sana Laboratories | $706.65 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.75 | 2024-2025 | Xifaxan, Relistor |
| Novo Nordisk INC | $267.49 | 2024 | Wegovy |
| Janssen Biotech, INC. | $252.96 | 2025 | Tremfya |
| Pfizer INC. | $232.02 | 2024-2025 | |
| Enterra Medical, INC. | $175.30 | 2025 | |
| Lilly USA, LLC | $133.30 | 2025 | Omvoh, Zepbound |
| Ardelyx, INC. | $128.53 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $108.03 | 2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $107.77 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $74.74 | 2025 | Zenpep |
| Vivus LLC | $68.05 | 2024-2025 | Pancreaze, Qsymia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $55.06 | 2024 | Kristalose |
| Exact Sciences Corporation | $51.55 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ipsen Biopharmaceuticals, INC | $47.43 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $44.12 | 2025 | Entyvio, Gattex |
| Pharmacosmos Therapeutics INC. | $40.96 | 2024-2025 | Monoferric |
| Intercept Pharmaceuticals, INC. | $34.08 | 2025 | |
| Evoke Pharma, INC. | $24.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ashamalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.